SUVEN LIFE SCIENCES LTD. - 530239 - Clarification
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Suven Life Sciences Ltd has submitted to BSE a copy of Clarification is enclosed. Suven Life Sciences Ltd - 530239 - Clarification sought from Suven Life Sciences Ltd
The Exchange has sought clarification from Suven Life Sciences Ltd on 03rd February, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. SUVEN LIFE SCIENCES LTD. - 530239 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from Shareholder of the Company, regarding loss of share certificate(s) as details mentioned below. A copy of request letter received from Shareholder is enclosed herewith.
Suven Life Sciences shares trade ex-demerger, record date on Jan 22
The record date for demerger is January 22, which means the person has to have Suven Life's shares in his/her account by end of this day and then he/she will be eligible for shares of CRAMs business. Suven Life Sciences Ltd - 530239 - Cost Of Acquisition - Post Demerger - Suven Life Sciences Ltd
Please find enclosed herewith communication being issued for general guidance of shareholders of the Company in relation to apportionment of the cost of acquisition of shares of Suven Life Sciences Limited and Suven Pharmaceuticals Limited as per the provisions of the Income Tax Act, 1961. Suven Life Sciences Ltd - 530239 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from our RTA (KFin Technologies Private Limited) regarding loss of share certificate(s) from the following shareholders(s). A copy of intimation from RTA is enclosed herewith. Suven Life Sciences Ltd - 530239 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- SHRENIK SONIDesignation :- Company Secretary and Compliance Officer Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisements pertaining to Notice of Record Date SUVEN LIFE SCIENCES LTD. - 530239 - Shareholding for the Period Ended December 31, 2019
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Change in Directorate
Shri D. G. Prasad, the Independent Director has demitted his office of Director in Suven Life Sciences Ltd w.e.f. 10th January, 2020 and decided to continue as Independent Director on the Board of Suven Pharmaceuticals Limited as per the rearrangement of the compositions of the both Boards of Suven Life Sciences Ltd and Suven Pharmaceuticals Ltd as approved by the respective Boards. Mr. D. G. Prasad had already joined the Board of Suven Pharmaceuticals Ltd as its Independent Director w.e.f. 30th November, 2019